http://www.physorg.com/ en-us Physorg.com internet news portal provides the latest news on science including: Physics, Nanotechnology, Life Sciences, Space Science, Earth Science, Environment, Health and Medicine. Can treatments that reduce risks for cardiovascular disease (CVD) also help combat age-related macular degeneration (AMD), an eye disease that affects millions of Americans? CVD and AMD share some risk factors-such as smoking, high blood pressure, and inflammation-and a recent study found that people who have early-stage AMD are more likely to develop heart disease. This month's Ophthalmology, the journal of the American Academy of Ophthalmology, reports on how two heart disease treatments, low-dose aspirin and statin medications, may impact AMD risk and disease progression. http://www.physorg.com/news178892149.html Medicine & Health Tue, 01 Dec 2009 12:17:06 EST news178892149 (PhysOrg.com) -- A team of researchers has implemented support for 'trusted computing' in a commercially available version of the open source operating system Linux, breaking new ground in the global drive toward more secure computing environments. http://www.physorg.com/news177931452.html Technology Fri, 20 Nov 2009 09:40:02 EST news177931452 Can Intel and Advanced Micro Devices, Silicon Valley's version of the long-squabbling Hatfields and McCoys, really get along? http://www.physorg.com/news177859569.html Technology Thu, 19 Nov 2009 13:40:01 EST news177859569 An upgrade to a Cray XT5 high-performance computing system deployed by the Department of Energy has made the "Jaguar" supercomputer the world's fastest. Located at Oak Ridge National Laboratory, Jaguar is the scientific research community's most powerful computational tool for exploring solutions to some of today's most difficult problems. The upgrade, funded with $19.9 million under the Recovery Act, will enable scientific simulations for exploring solutions to climate change and the development of new energy technologies. http://www.physorg.com/news177608722.html Electronics Mon, 16 Nov 2009 16:30:02 EST news177608722 (AP) -- Intel Corp. is paying Silicon Valley rival Advanced Micro Devices Inc. $1.25 billion to squash a legal battle over Intel's sales tactics, a rift that led to antitrust charges against Intel in several countries and was headed toward a costly and nasty trial next year. http://www.physorg.com/news177247607.html Technology Thu, 12 Nov 2009 11:27:43 EST news177247607 Age-related macular degeneration does not appear to progress at a higher rate among individuals who have had surgery to treat cataract, contrary to previous reports that treating one cause of vision loss worsens the other, according to a report in the November issue of Archives of Ophthalmology. http://www.physorg.com/news177010517.html Medicine & Health Mon, 09 Nov 2009 19:40:01 EST news177010517 (AP) -- New York's attorney general hit Intel Corp. with an antitrust lawsuit Wednesday, claiming the company used "illegal threats and collusion" to dominate the market for computer microprocessors. http://www.physorg.com/news176556879.html Technology Wed, 04 Nov 2009 11:35:22 EST news176556879 Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular endothelial growth factor (VEGF), i.e. one that when secreted can reach other cells at a distance, the retina shows defects similar to "dry" macular degeneration, also called geographic atrophy (GA). This finding, published in the November 3, 2009 print edition of PNAS (Proceedings of the National Academy of Sciences), not only increases the understanding of the causes of this blinding disease, but it may also impact the use of anti-VEGF drugs, such as Lucentis, which are designed to neutralize VEGF in eyes with "wet" macular degeneration. http://www.physorg.com/news176401950.html Medicine & Health Mon, 02 Nov 2009 16:50:02 EST news176401950 (AP) -- Chip maker Advanced Micro Devices Inc. is "thoroughly reviewing" published reports fingering former chairman and CEO Hector Ruiz as the AMD executive who gave confidential company information to a defendant in the Galleon Group insider trading case. http://www.physorg.com/news175929971.html Technology Wed, 28 Oct 2009 06:40:03 EST news175929971 The world's fastest supercomputer, Roadrunner, at Los Alamos National Laboratory has completed its initial "shakedown" phase doing accelerated petascale computer modeling and simulations of a variety of unclassified, fundamental science projects. http://www.physorg.com/news175781501.html Electronics Mon, 26 Oct 2009 13:13:49 EST news175781501 A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO). http://www.physorg.com/news175778678.html Medicine & Health Mon, 26 Oct 2009 12:50:01 EST news175778678 Producing your own high-definition video has become increasingly easier with today's line of HD video cameras. But transferring the content from your computer to a TV can be a challenge. http://www.physorg.com/news175413173.html Electronics Thu, 22 Oct 2009 10:50:02 EST news175413173 (PhysOrg.com) -- AMD announced today eight new, low cost, Athlon II processors to their Athlon II processor family. http://www.physorg.com/news175267985.html Electronics Tue, 20 Oct 2009 14:33:40 EST news175267985 (AP) -- Advanced Micro Devices Inc. lost money in the third quarter but said Thursday that sales were stronger than expected, adding to mounting evidence that consumer spending is fueling a turnaround in the personal computer market. http://www.physorg.com/news174847125.html Technology Thu, 15 Oct 2009 17:39:11 EST news174847125 Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in the American Journal of Ophthalmology, is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial comparing Bevacizumab to Ranibizumab for the treatment of exudative (wet) age-related macular degeneration. http://www.physorg.com/news174302546.html Medicine & Health Fri, 09 Oct 2009 10:50:02 EST news174302546